Oncternal Therapeutics (Oncternal Therapeutics) Beneish M-Score : 0.00 (As of Apr. 26, 2024)

View and export this data going back to 2004. Start your Free Trial

What is Oncternal Therapeutics Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

The historical rank and industry rank for Oncternal Therapeutics's Beneish M-Score or its related term are showing as below:

During the past 13 years, the highest Beneish M-Score of Oncternal Therapeutics was 0.00. The lowest was 0.00. And the median was 0.00.

Oncternal Therapeutics Beneish M-Score Historical Data

The historical data trend for Oncternal Therapeutics's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oncternal Therapeutics Beneish M-Score Chart

Oncternal Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Beneish M-Score

Get a 7-Day Free Trial

Oncternal Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Beneish M-Score	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Oncternal Therapeutics's Beneish M-Score

For the Biotechnology subindustry, Oncternal Therapeutics's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Oncternal Therapeutics's Beneish M-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oncternal Therapeutics's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Oncternal Therapeutics's Beneish M-Score falls into.

Oncternal Therapeutics Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Oncternal Therapeutics for today is based on a combination of the following eight different indices:

-4.84

0.92 * DSRI

0.528 * GMI

0.404 * AQI

0.892 * SGI

0.115 * DEPI

-4.84

0.92 *

0.528 *

0.404 *

0.892 *

0.115 *

0.172 * SGAI

4.679 * TATA

0.327 * LVGI

0.172 *

4.679 *

0.327 *

This Year (Dec23) TTM:

Last Year (Dec22) TTM:

Total Receivables was $0.63 Mil.
Revenue was 0 + 0 + 0 + 0 = $0.00 Mil.
Gross Profit was 0 + 0 + 0 + 0 = $0.00 Mil.
Total Current Assets was $36.06 Mil.
Total Assets was $36.73 Mil.
Property, Plant and Equipment(Net PPE) was $0.26 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.00 Mil.
Selling, General, & Admin. Expense(SGA) was $12.75 Mil.
Total Current Liabilities was $5.20 Mil.
Long-Term Debt & Capital Lease Obligation was $0.15 Mil.
Net Income was -9.164 + -9.862 + -8.966 + -11.487 = $-39.48 Mil.
Non Operating Income was 0 + 0 + 0 + 0 = $0.00 Mil.
Cash Flow from Operations was -6.419 + -5.513 + -9.263 + -10.969 = $-32.16 Mil.

Total Receivables was $0.18 Mil.
Revenue was 0 + 0 + 0 + 0 = $0.00 Mil.
Gross Profit was 0 + 0 + 0 + 0 = $0.00 Mil.
Total Current Assets was $67.29 Mil.
Total Assets was $68.65 Mil.
Property, Plant and Equipment(Net PPE) was $0.09 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.00 Mil.
Selling, General, & Admin. Expense(SGA) was $13.46 Mil.
Total Current Liabilities was $7.68 Mil.
Long-Term Debt & Capital Lease Obligation was $0.00 Mil.

1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI	=	(Receivables_t / Revenue_t)	/	(Receivables_t-1 / Revenue_t-1)
	=	(0.632 / 0)	/	(0.178 / 0)
	=		/
	=

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI	=	GrossMargin_t-1	/	GrossMargin_t
	=	(GrossProfit_t-1 / Revenue_t-1)	/	(GrossProfit_t / Revenue_t)
	=	(0 / 0)	/	(0 / 0)
	=		/
	=

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI	=	(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t)	/	(1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
	=	(1 - (36.059 + 0.258) / 36.729)	/	(1 - (67.29 + 0.087) / 68.651)
	=	0.011217	/	0.018558
	=

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI	=	Sales_t	/	Sales_t-1
	=	Revenue_t	/	Revenue_t-1
	=	0	/	0
	=

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI	=	(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1))	/	(Depreciation_t / (Depreciaton_t + PPE_t))
	=	(0 / (0 + 0.087))	/	(0 / (0 + 0.258))
	=	0	/	0
	=

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI	=	(SGA_t / Sales_t)	/	(SGA_t-1 /Sales_t-1)
	=	(12.746 / 0)	/	(13.457 / 0)
	=		/
	=

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI	=	((LTD_t + CurrentLiabilities_t) / TotalAssets_t)	/	((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
	=	((0.145 + 5.198) / 36.729)	/	((0 + 7.682) / 68.651)
	=	0.145471	/	0.111899
	=

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA	=	(IncomefromContinuingOperations_t	-	CashFlowsfromOperations_t)	/	TotalAssets_t
	=	(NetIncome_t - NonOperatingIncome_t	-	CashFlowsfromOperations_t)	/	TotalAssets_t
	=	(-39.479 - 0	-	-32.164)	/	36.729
	=	-0.199161

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Oncternal Therapeutics Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Oncternal Therapeutics's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.

Oncternal Therapeutics (Oncternal Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncternal Therapeutics Inc (NAS:ONCT) » Definitions » Beneish M-Score

Comparable Companies

Traded in Other Exchanges

GTU:Germany

Address

12230 El Camino Real, Suite 230, San Diego, CA, USA, 92130

Website

https://www.oncternal.com

Oncternal Therapeutics Inc is a clinical-stage oncology company developing first-in-class, novel therapies that target a broad spectrum of cancers with a large unmet medical need. The Company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to ROR1 (Receptor-tyrosine kinase-like Orphan Receptor 1), and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins. The Company is also developing ONCT-808, a CAR-T (chimeric antigen receptor T-cells) product candidate that targets ROR1 and ONCT-534, a dual-action androgen receptor inhibitor product candidate for the treatment of castration-resistant prostate and other androgen receptor-driven cancers.

Executives

Gunnar F. Kaufmann	officer: Chief Scientific Officer	C/O ONCTERNAL THERAPEUTICS, INC., 12230 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
Salim Yazji	officer: Chief Medical Officer	12230 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
James B Breitmeyer	director, officer: President, CEO
Richard G Vincent	officer: Chief Financial Officer	C/O WOMEN FIRST HEALTH CARE, 5355 MIRA SORRENTO PLACE STE. 700, SAN DIEGO CA 92121-3825
Chase C. Leavitt	officer: General Counsel/Secretary	1010 ATLANTIC AVENUE, SUITE 102, ALAMEDA CA 94501
Jill Desimone	director	C/O PRAXIS PRECISION MEDICINES, INC., 99 HIGH STREET, 30TH FLOOR, BOSTON MA 02110
Rajesh Krishnan	officer: Chief Technology Officer	12230 EL CAMINO, SUITE 300, SAN DIEGO CA 92130
Jinzhu Phd Chen	director	12230 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
Michael G Carter	director	C/O CANCER VAX CORP, 2110 RUTHERFORD ROAD, CARLSBAD CA 92008
Daniel L Kisner	director	2292 FARADAY AVENUE, CARLSBAD CA 92008
Shanghai Pharmaceuticals Holding Co., Ltd.	10 percent owner	C/O ONCTEMAL THERAPEUTICS, INC., 12230 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
Shanghai Pharmaceuticals (hk) Investment Ltd	10 percent owner	C/O ONCTERNAL THERAPEUTICS, INC., 12230 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
Shanghai Pharmaceutical (usa) Inc.	10 percent owner	C/O ONCTERNAL THERAPEUTICS, INC., 3525 DEL MAR HEIGHTS ROAD #821, SAN DIEGO CA 92130-2122
Hazel M Aker	officer: General Counsel	C/O CANCER VAX CORP, 2110 RUTHERFORD ROAD, CARLSBAD CA 92008
Man Cho	director	C/O ONCTERNAL THERAPEUTICS, INC., SUITE 300, SAN DIEGO CA 92130